Rocking the foundations of solid tumor growth by attacking the tumor's blood supply

被引：40

作者：

Molema, G

Griffioen, AW

机构：

[1] Groningen Utrecht Inst Drug Explorat, Dept Clin Immunol, Sect Tumor Immunol, NL-9713 GZ Groningen, Netherlands

[2] Groningen Utrecht Inst Drug Explorat, Dept Pharmacokinet & Drug Delivery, NL-9713 GZ Groningen, Netherlands

[3] Univ Hosp Maastricht, Dept Internal Med, Tumor Angiogenesis Lab, NL-6202 AZ Maastricht, Netherlands

来源：

IMMUNOLOGY TODAY | 1998年 / 19卷 / 09期

关键词：

D O I：

10.1016/S0167-5699(98)01314-0

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Deprivation of tumor vascularization is a promising way to prevent tumor outgrowth. Various approaches are under investigation to achieve this, ranging from inhibition of endothelial cell growth or migration to selective tumor vascular targeting of chemotherapeutics. The rapid progress in the field of angiogenesis research, including results presented at a recent meeting*, is discussed here.

引用

页码：392 / 394

页数：3

共 15 条

[1] Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) [J].

Achen, MG ;

Jeltsch, M ;

Kukk, E ;

Mäkinen, T ;

Vitali, A ;

Wilks, AF ;

Alitalo, K ;

Stacker, SA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :548-553

[2] Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].

Arap, W ;

Pasqualini, R ;

Ruoslahti, E .

SCIENCE, 1998, 279 (5349) :377-380

[3] Cancer research - Designing therapies that target tumor blood vessels [J].

Barinaga, M .

SCIENCE, 1997, 275 (5299) :482-484

[4] Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J].

Boehm, T ;

Folkman, J ;

Browder, T ;

OReilly, MS .

NATURE, 1997, 390 (6658) :404-407

[5] Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity [J].

Brooks, PC ;

Silletti, S ;

von Schalscha, TL ;

Friedlander, M ;

Cheresh, DA .

CELL, 1998, 92 (03) :391-400

[6] INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS [J].

BROOKS, PC ;

MONTGOMERY, AMP ;

ROSENFELD, M ;

REISFELD, RA ;

HU, TH ;

KLIER, G ;

CHERESH, DA .

CELL, 1994, 79 (07) :1157-1164

[7] TNP-470 (AGM-1470): Mechanisms of action and early clinical development [J].

Castronovo, V ;

Belotti, D .

EUROPEAN JOURNAL OF CANCER, 1996, 32A (14) :2520-2527

[8] Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning [J].

Davis, S ;

Aldrich, TH ;

Jones, PF ;

Acheson, A ;

Compton, DL ;

Jain, V ;

Ryan, TE ;

Bruno, J ;

Radziejewski, C ;

Maisonpierre, PC ;

Yancopoulos, GD .

CELL, 1996, 87 (07) :1161-1169

[9] Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature [J].

Huang, XM ;

Molema, G ;

King, S ;

Watkins, L ;

Edgington, TS ;

Thorpe, PE .

SCIENCE, 1997, 275 (5299) :547-550

[10] Hyperplasia of lymphatic vessels in VEGF-C transgenic mice [J].

Jeltsch, M ;

Kaipainen, A ;

Joukov, V ;

Meng, XJ ;

Lakso, M ;

Rauvala, H ;

Swartz, M ;

Fukumura, D ;

Jain, RK ;

Alitalo, K .

SCIENCE, 1997, 276 (5317) :1423-1425

← 1 2 →